MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia
eJHaem · 2024-02 · 5 (1) · 191-205
DOI: 10.1002/jha2.849 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift eJHaem, online erschienen am 11.02.2024. Verfasst von Afgar Ali und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Hydatid Disease in Iran Kerman University of Medical Sciences Kerman Iran. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Small noncoding ribonucleic acids called microRNAs coordinate numerous critical physiological and biological processes such as cell division, proliferation, and death. These regulatory molecules interfere with the function of many genes by binding the 3'‐UTR region of target mRNAs to inhibit their translation or even degrade them. Given that a large proportion of miRNAs behave as either tumor suppressors or oncogenes, any genetic or epigenetic aberration changeing their structure and/or function could initiate tumor formation and development. An example of such cancers is chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in Western nations, which is caused by unregulated growth and buildup of defective cells in the peripheral blood and lymphoid organs. Genetic alterations at cellular and molecular levels play an important role in the occurrence and development of CLL. In this vein, it was noted that the development of this disease is noticeably affected by changes in the expression and function of miRNAs. Many studies on miRNAs have shown that these molecules are pivotal in the prognosis of different cancers, including CLL, and their epigenetic alterations (e.g., methylation) can predict disease progression and response to treatment. Furthermore, miRNAs are involved in the development of drug resistance in CLL, and targeting these molecules can be considered a new therapeutic approach for the treatment of this disease. MiRNA screening can offer important information on the etiology and development of CLL. Considering the importance of miRNAs in gene expression regulation, their application in the diagnosis, prognosis, and treatment of CLL is reviewed in this paper.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Center for Hydatid Disease in Iran Kerman University of Medical Sciences Kerman Iran.
- Stem Cells and Regenerative Medicine Innovation Center Kerman University of Medical Sciences Kerman Iran.
- Department of Hematology and Laboratory Sciences, Faculty of Allied Medical Sciences Kerman University of Medical Sciences Kerman Iran.
- Department of Medical Genetics, School of Medicine Tehran University of Medical Sciences Tehran Iran.
- Research Center of Tropical and Infectious Diseases Kerman University of Medical Sciences Kerman Iran.
- Department of Research and Development, Production and Research Complex Pasteur Institute of Iran Tehran Iran.
ORCID-Profile: Arezoomand Hossein
Zitieren
APA
Ali, A., Mahla, S. B., Reza, V., Hossein, A., Bahareh, K., Mohammad, H., Fatemeh, S., Mostafa, A. B., & Leili, R. (2024). MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia. eJHaem, 5(1), 191-205. https://doi.org/10.1002/jha2.849
Vancouver
Ali A, Mahla SB, Reza V, Hossein A, Bahareh K, Mohammad H, et al. MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia. eJHaem. 2024;5(1):191-205. doi:10.1002/jha2.849
BibTeX
@article{Ali2024,
author = {Ali, Afgar and Mahla, Sattarzadeh Bardsiri and Reza, Vahidi and Hossein, Arezoomand and Bahareh, Kashani and Mohammad, Hosseininaveh and Fatemeh, Sharifi and Mostafa, Amopour Bahnamiry and Leili, Rouhi},
title = {MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia},
journal = {eJHaem},
year = {2024},
volume = {5},
number = {1},
pages = {191--205},
doi = {10.1002/jha2.849}
}
EUVIMED